Close
  Indian J Med Microbiol
 

Figure 1: ROCs of PSA, PSAD, and PSA-AV, (a) predicting the result of prostate cancer in the entire population, (b) predicting the result of high-grade prostate cancer with Gleason Score ≥8 in the entire population, (c) predicting the result of prostate cancer in the subgroup with PSA ranging from 2.0 ng ml−1 to 20.0 ng ml−1, (d) predicting the result of high-grade prostate cancer with Gleason Score ≥8 in the subgroup with PSA ranging from 2.0 ng ml−1 to 20.0 ng ml−1. ROC: receiver operating characteristic curve; PSA: total prostate-specific antigen; PSA-AV: prostate-specific antigen-age volume; PSAD: prostate-specific antigen density.

Figure 1: ROCs of PSA, PSAD, and PSA-AV, (<b>a</b>) predicting the result of prostate cancer in the entire population, (<b>b</b>) predicting the result of high-grade prostate cancer with Gleason Score ≥8 in the entire population, (<b>c</b>) predicting the result of prostate cancer in the subgroup with PSA ranging from 2.0 ng ml<sup>−1</sup> to 20.0 ng ml<sup>−1</sup>, (<b>d</b>) predicting the result of high-grade prostate cancer with Gleason Score ≥8 in the subgroup with PSA ranging from 2.0 ng ml<sup>−1</sup> to 20.0 ng ml<sup>−1</sup>. ROC: receiver operating characteristic curve; PSA: total prostate-specific antigen; PSA-AV: prostate-specific antigen-age volume; PSAD: prostate-specific antigen density.